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Open access under CC BDibutyl phthalate (DBP) is mainly taken up by the general popu lation from food intake. To estimate 
intake of phthalate s, determining distribution and accumulation of DBP in biological materials was a crit- 
ical need. In this work, we set up two novel approaches with a monoclonal antibody speciﬁc to DBP to 
determine the distribution and accumulation of DBP in vivo. The contents of DBP in liver, kidney, stomach 
and testes were detected by immunoﬂuorescence assays and indirect competitive ELISA. This data give 
directly evidence that indicates the distribution and accumul ation of DBP in vivo. Double-label immuno- 
ﬂuorescence assay provides wit h a visual approach to determina tion of the distribution and accumulation 
of DBP. It indicated that DBP accumulated in subcutaneous tissue such as sweat gland, hair follicle. Both 
of immunoﬂuorescence assay and ELISA can be used to detect the content of DBP in biological materials. 
Our assays showed that DBP accumulated in viscera being rich in fat, such as liver, kidney and could over- 
come physiological barrie rs to penetrate testes. The date suggested that the accumulations of DBP 
exposed through dermal route were less than that of oral route and most of DBP was metabolized in 2
or 3 days. 
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction 
In recent years, plasticize r contaminat ion triggers food security 
fear in many countries and regions. Phthalates are a group of syn- 
thetic chemicals with widespread use in the industrial production 
of numerous consumer products. They are used to soften plastics 
found in numerous ﬂexible plastics products and personal care 
products such as food packagin g and food-contact materials, cos- 
metics, toys, bags, drugs and building materials. During the last 
thirty years, numerous studies have been published concerning ; CR, cross-reactivity; DBAP, 
ISA, enzyme-linked immuno- 
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Y-NC-ND license.the presence of phthalate compounds in food and packaging mate- 
rials (Cao, 2010; Fierens et al., 2012 ).
Phthalate esters are suspected to be involved in male reproduc- 
tive health problems and have also been associated with several 
other health problems including obesity, diabetes, allergy, and 
asthma (Borch et al., 2006; Bornehag and Nanberg, 2010; Engel 
et al., 2010; Hauser et al., 2007; Matsuda et al., 2010; Ormond 
et al., 2009; Stahlhut et al., 2007; Stroheker et al., 2006 ). Among 
all phthalate esters, dibutyl phthalate (DBP) is second only to di- 
(2-ethylhexyl) phthalate in terms of such effects (Huang et al., 
1999; Yie, 1993 ).
DBP is a phthalate diester that is used mainly as a plasticize r for 
nitrocellul ose, polyvinyl acetate, and polyvinyl chloride; a lubri- 
cant; an antifoami ng agent; and a skin emollient (Koo and Lee, 
2004). DBP, the main kind of plasticizers used in China at present, 
is one of the main sources of indoor semi-volatile organic com- 
pounds (SVOCs) (Wang et al., 2010 ). DBP is a developmental toxi- 
cant in rats and mice (Fisher et al., 2003; Foster et al., 2000; Lamb 
IV et al., 1987 ). It is known to affect male fertility, cause testicular 
atrophy in young rats, and produce embryomortal ity and teratoge- 
nicity, in rodents (Gray et al., 1999, 2000; Kavlock et al., 2002; 
Moore et al., 2001; Mylchreest et al., 1998, 1999, 2000 ). Besides 
its role as endocrine disruptor, DBP has been shown to alter the 
expression of a number of genes. Expressions of 391 genes have 
been found signiﬁcantly altered as a result of the exposure to 
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ried (Euling et al., 2011; Liu et al., 2005 ). DBP is metabolized to 
monobutyl phthalate (MBP) in the stomach and small intestine 
and enters the bloodstream. The pharmacokine tics of DBP have 
been investigated in rats in experimental studies (Clewell et al., 
2009). MBP and its primary metabolite, monobut yl phthalate –
glucuronide (MBP-G), were measured in maternal and fetal after 
DBP doses where developmen tal effects have been found. MBP 
has been reported to be the active species responsible for adverse 
effects from DBP exposure (Ema et al., 1996; Kremer et al., 2005 ). It 
has been reported that both DBP and MBP suppress steroidogen e- 
sis by fetal-type Leydig cells in rats, but similar effects in vitro can- 
not be studied in primate (Hallmark et al., 2007 ).
DBP enters the environm ent in several different ways. These in- 
clude: during production, distribution, and incorporation into 
polyvinylch loride resin; disposal in industrial and municipal land- 
ﬁlls; waste incineration ; and leaching from consumer products 
during use or after disposal. Because of its low vapor pressure, con- 
centrations of DBP in outdoor air are low; they range from 100 to 
102 ng/m 3 (Luks-Betlej et al., 2001 ). Although outdoor concentra- 
tions of DBP are low, indoor concentratio ns of DBP are relatively 
high (Weschler and Nazaroff, 2008 ). It is among the most abundan t
‘‘manmade’’ SVOC commonly measured in indoor air and in settled 
dust. DBP is very stable and can enter the aquatic environment. 
There is a potential risk for ecotoxicological effects of DBP on aqua- 
tic species. Concentrations above 0.04 mg/L are shown to cause ad- 
verse effects on aquatic invertebrates and concentratio ns above 
0.2 mg/L can have lethal effects. Although DBP can be biodegra ded 
as a short chains phthalate, the degradation process is time- 
consuming in anaerobic environments. It has some potential to 
bioaccumulate in some organisms. 
Because of its large and widespread use DBP is taken up by the 
general population from various sources (Clark et al., 2003; 
Wormuth et al., 2006 ). For humans, food intake is the most impor- 
tant exposure pathway for phthalates, followed by ingestion of 
dust and inhalation of indoor (Dickson- Spillmann et al., 2009; Jan- 
jua et al., 2008; Petersen and Jensen, 2010; Schlump f et al., 2010; 
Weschler and Nazaroff, 2012; Wormuth et al., 2006 ). Intake of 
phthalates via food might cause different effects comparing with 
the routes by ingestion of dust and inhalation of indoor air. Studies 
to evaluate the potential adverse effects of exposure to dibutyl 
phthalate through various routes were a critical need. 
Phthalate metaboli te concentrations measured in urine samples 
were used to estimate phthalate daily intake in previous re- 
searches (Ferguson et al., 2011 ).To evaluate the potential adverse 
effects of exposure to DBP, the concentration of DBP and MBP, 
the major metabolite of DBP, in the blood and urine was often 
determined by gas chromatography , liquid chromatograp hy and 
mass spectroscopy (Jen and Liu, 2006; Serodio and Nogueira ,
2006; Zhang et al., 2008 ). The mean concentratio ns of MBP in urine 
were measured in the United States according to the National 
Health and Nutrition Examination Survey (NHANES). While MBP, 
the principal metabolite of DBP, has been measure d in blood and 
urine in numerous studies, there are no studies that have mea- 
sured DBP, itself, in blood or urine. And the environmental data 
consist primarily of estimate s. 
DBP concentrations are often either at or below detection limits. 
It is expensive and difﬁcult to determine the concentr ation of DBP 
in organism. Although, the chromatograp hic techniqu es provide a
low level of detection for phthalates, they are time consuming 
and have high instrumenta tion costs. To evaluate the potential ad- 
verse effects of exposure to dibutyl phthalate, methods for dibutyl 
phthalate determination must be developed. 
In this work, we set up two novel approaches to determinati on 
of distribution and accumulation of DBP in vivo with a monoclonal 
antibody speciﬁc to DBP (Wei et al., 2011 ).The described assay can provide useful estimates of excretion, distribution and metabolism 
of DBP through different routes. 2. Materials and methods 
2.1. Animals 
Six-week-old male Wistar rats arrived from Hubei Center for Disease Control 
and were housed in the Animal Care Facility of Central China Normal University, 
which is accredited by the Association for Assessment and Accreditation of Labora- 
tory Animal Care National. The animals were housed 2 or 3/cage on wood-chip bed- 
ding in an air-conditioned animal room at 22 ± 3 C and 55% ± 10% humidity with a
12/12 h light–dark cycle and allowed free access to powdered diet and ﬁltered tap 
water.2.2. Treatment 
DBP (Sigma–Aldrich) was dissolved in corn oil (99.5% pure, Shanghai Solvent 
Factory, Shanghai, China). Wistar rats (n = 5/group) were administered either di- 
butyl-phthalate (DBP – Sigma–Aldrich) or corn oil by epicutaneously exposure 
(cutaneous route) or gavage (oral route). For dermal exposure, rat abdomens were 
shaved using small animal clippers one day before exposure. Rats were epicutane- 
ously smeared with DBP at 200, 400 mg/kg bw-d or corn oil. For oral route, Wistar 
rats (n = 5/group) were administered either dibutyl-phthalate (DBP – Sigma–Al-
drich) at dose of 200, 400 mg/kg bw-d, by gavage (oral route), or corn oil (vehicle).
Starting 24, 48, 72 h after the ﬁnal treatment, the rats were euthanized. Skin, liver, 
kidney, stomach, testes from each rats were collected, snap frozen in liquid nitro- 
gen, and stored individually at 80 C.2.3. Preparation for monoclonal antibody 
Anti-DBP monoclonal antibody (MAb) was prepared according to Wei et al. 
(2011). Dibutyl 4-aminophthalate (DBAP), an aminated hapten with structural fea- 
ture of DBP, was linked to BSA or OVA through diazotization to generate artiﬁcial
antigen DBAP-BSA or DBAP-OVA. All the hapten-protein conjugates were character- 
ized by UV–vis spectrometry. Then BALB/c mice were immunized with these artiﬁ-
cial antigens. Mice were tail-bled 7–10 days after the third and the fourth injection. 
Indirect noncompetitive ELISA (inELISA) and Indirect competitive ELISA (icELISA)
with 1.0 lg/mL heterologous coating protein conjugates were used to determine 
the titer and sensitivity of antibody in the serum. The mouse that generated poly- 
clonal antibody with a combination of the best sensitivity and the highest titer re- 
ceived a ﬁnal intraperitoneal injection of 200 lg of immunogen in 200 lL of PBS, 
3 days before cell fusion. Cell fusion, hybridoma culture and selection were carried 
out essentially as described by Wei et al. (2011). Then female BALB/c mice were in- 
jected intraperitoneally with 0.5 mL of parafﬁn oil 7–10 days before receiving an 
intraperitoneal injection of 2  106 hybridoma cells suspended in PBS. Ascites ﬂuid
developed 2–3 weeks after the injection of the cells and was collected every other 
day for 6 days (James, 1995 ). The ascites ﬂuid was centrifuged at 450 g for 5 min to 
remove cell pellet. The supernatant was diluted with equal volume of PBS and 
appropriate amount of silica dioxide (15 mg/mL) was added to the supernatant 
and incubated at room temperature for 30 min with rotation. The IgG from the pre- 
treated ascites ﬂuid was puriﬁed by caprylic acid/ammonium sulfate precipitation 
twice and dialysis and then stored at 70 C. The concentration and purity of puri- 
ﬁed MAb were determined by taking absorbance at 280 nm and SDS–polyacryl-
amide gel electrophoresis, respectively. 2.4. Determining for the titer of anti-DBP MAb 
Checkerboard titration, in which puriﬁed MAb was titrated against varying 
amounts of the coating hapten-conjugate was used to measure the reactivity of 
antibodies and to select an appropriate coating concentrations and antibody dilu- 
tions for icELISA (Crowther, 2001 ). The checkerboard assays were performed with 
inELISA. Microtiter plates were coated with 100 lL/well of hapten-protein conju- 
gates (0, 0.25, 0.5, and 1 lg/mL) in 0.05 mol/L carbonate buffer (pH 9.6) and incu- 
bated overnight at 4 C. The plates were washed three times with PBST (0.01 mol/ 
L PBS containing 0.05% Tween-20, pH7.4, 200 lL/well) and were blocked with 3% 
(w/v) skim milk powder in PBS (250 lL/well) for 1 h at 37 C. After another washing 
step, 100 lL/well of puriﬁed anti-DBP MAb (1:200, 1:400, 1:800, 1:1600, 1:3200, 
1:6400) diluted in PBS containing 0.1% BSA was added. After incubation for 1.5 h
at 25 C, the plates were washed Subsequently, the plates were incubated for 1 h
at 37 C with 8000-fold diluted HRP anti-mIgG in PBS containing 0.1% BSA 
(100 lL/well). After another washing step, 100 lL/well of freshly prepared O-phen- 
ylenediamine (OPD) solution (0.4 mg/mL OPD and 0.012% H2O2 in 0.05 mol/L cit- 
rate–phosphate, pH 5.0) was added. The reaction was stopped with 2 mol/L 
sulfuric acid (50 lL/well) after an incubation of 15 min at room temperature keep- 
ing away from light. The absorbance was recorded at a primary wavelength of 
492 nm with a reference wavelength of 630 nm. 
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To determine the speciﬁcity of MAb, the ability of the MAb to recognize several 
structurally related compounds (analogues) was tested by performing hapten 
coated icELISA (Wei et al., 2011 ) and determining their respective IC 50 (the concen- 
tration of analyte giving 50% inhibition) values. The cross-reactivity (CR) values 
were calculated according to the following equation CR (%) = IC 50 DBP/IC50 ana-
logue  100. The hapten coated icELISA was modiﬁed to determine whether MBP 
affects the binding of DBP to the MAb. The increasing concentration of MBP 
(19.5–10,000 lg/mL) was added to the 12.5 lg/L of DBP, then twice as the titer of 
the anti-DBP Mab in 50 lL of assay buffer was added to the wells in the ‘‘competi- 
tion’’ step of icELISA. The other procedures were the same as hapten coated icELISA 
under optimal condition. 2.6. Frozen sections 
Each excised sample was immediately frozen in liquid nitrogen. The specimens 
were embedded in tissue freeze media optimum cutting temperature (OCT) com- 
pound (Electron Microscopy Sciences, Hatﬁeld, PA) and frozen at 80 C freezer. 
Several frozen sections (5–10 lm thickness) were cut from each sample. Each sec- 
tion was dried in 37 C for 1 h. It was ﬁxed in 4% Paraformaldehyde 30 min and then 
washed 3 times in PBS. Table 2
Cross-reactivity of some compounds structurally relat ed to DBP by hapten coated 
icELISA. 
Analyte IC 50 (ng/ml)a CR% 
DBP 17.7 ± 3.2 100 
DBAP 64.7 ± 14.1 27.4 
MBP – 7.3% inhibition at 10 mg/ml 
DMP – 7.98% inhibition at 10 mg/ml 
DEP – 5.08% inhibition at 10 mg/ml 
DEHP – 1.12% inhibition at 10 mg/ml 
DOP – 1.15% inhibition at 10 mg/ml 
a Each data represents the mean of ± SD of three replicates (three plates on the 2.7. Immunoﬂuorescence assays 
Each specimen was embedded, sectioned and ﬁxed. Washed with PBS, the fro- 
zen sections were blocked with 5% milk in PBS at room temperature for 1 h and 
then incubated at 4 C overnight with the puriﬁed anti-DBP antibody (1:100
dilution with 1% milk in PBS). After washes in PBS containing 0.1% Tween-20, all 
samples were incubated with a secondary antibody (ﬂuorescein isothiocyanate- 
conjugated, afﬁnity-puriﬁed goat-rabbit IgG) at 1:100 dilution in PBS containing 
2% Goat Serum for 1 h at room temperature under dark. All sections were 
counterstained with 3,8-Diamino-5-[3-(diethylmethylammonio)propyl]-6-phen-
ylphenanthridinium diiodide (PI). Sections were mounted with Vectashield (Bruns-
chwig chemie, Amsterdam, The Netherlands) and coverslipped. Observations and 
photography were obtained with an Axioskop 40 microscope equipped with epi- 
ﬂuorescence optics and a cool-CCD camera (Zeiss) or a confocal microscope (Leica,
Heerbrugg, Switzerland).same day).2.8. Conjugate coated indirect competitive ELISA 
An icELISA was used to assess the sensitivity of the MAb to free DBP and the 
crossreactivities of structurally related compounds to the antibody. N,N-dimethyl- 
formamide (DMF) was used to prepare standard solution and assay buffer 
(0.01 mol/L PBS containing 0.1% BSA, 10% DMF and 1.6% NaCl). For competition, 
50 lL of standards or diluted samples in assay buffer were placed in the wells, 
and 50 lL of the anti-DBP MAb diluted with assay buffer was added. After incu- 
bated for 1.5 h at 25 C, the plate was washed. The following procedure was fol- 
lowed as described for the inELISA. With the icELISA format, analytes that do not 
react with the antibodies would produce the maximum absorbance; conversely, 
analytes that do react with the antibody would decrease in percentage of absor- 
bance. Standards and samples were run in triplicate wells, and the mean absor- 
bance values were processed. Standard curves were obtained by plotting 
absorbance against the analyte concentration and ﬁtted with a logistic three- 
parameter equation y = (AAi)/(AA0)  100, where A is the absorbance value with 
no analyte present, Ai is the absorbance value with analyte present, A0 is the absor- 
bance value of blank. Fig. 1. Determining whether MBP affects DBP binding to the anti-DBP MAb. 2.9. Statistical methods 
The contents of DBP were evaluated by immunoﬂuorescence assays and mea- 
surement of ﬂuorescence intensity using softer Image-Pro Plus . All analyses were 
performed using softer origin75. Table 1
Titers of anti-DBP MAb. 
Coating concentration (lg/mL) Times of dilution/absorbance at 492 n
200 400 
1 2.391 2.057 
0.5 2.034 1.847 
0.25 1.643 1.372 
a Absorbance at 492 nm under different concentrations of coating antigen (DBAP-OVA)
b The last dilution of MAb that gave an absorbance at 492 nm of >1.0 was judged as the3. Results 
3.1. Preparatio n for monoclon al antibody 
A monoclonal antibody speciﬁc to DBP was produced from a
stable hybridom a cell line resulting from the fusion of a mouse 
myeloma with B cells obtained from a mouse immunized with 
puriﬁed, artiﬁcial antigen DBAP-OVA. Indirect noncompetitive ELI- 
SA (inELISA) with 0.25, 0.5, 1 lg/mL DBAP-OVA as a coated antigen 
were used to determine the titer and sensitivity of anti-DBP MAb. 
The results of the titers of anti-DBP MAb are shown in Table 1. The 
optimal coating concentration of DBAP-OVA and dilution of MAb 
determined by checkerboard titration were 0.5 lg/mL and 1:1600 
(1 lg/mL), respectively. 3.2. The speciﬁcity of MAb 
We evaluated MAb recogniti on to some chemical s structurally 
resembli ng portions of DBP structure (Table 2). The most sensitive m 
800 1600 3200 6400 
1.752 1.408 1.110 0.803 
1.519 1.187 0.903 0.658 
1.107 0.846 0.576 0.413 
and times of dilution of MAb. 
 titer. 
Fig. 2. Adherence and internalization of DBP in dermas and subcutaneous tissue cells. (a) Group of 400 mg DBP and (b) negative control group. Ten rats were epicutaneously 
smeared with DBP at 400 mg/kg bw-d or corn oil for 3 days. The treated skin was collected, embedded, sectioned and ﬁxed. Each section was ﬁxed and processed for double- 
immunoﬂuorescence labeling. The DBP immersed in the cell was detected with the monoclonal antibody of DBP. PI-stained nuclei are shown in red. In merged images, DBP 
are shown green and nuclei are shown in red. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. DBP accumulations in sweat gland. 
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all of the other compounds tested, the CRs achieved were very low 
except that for DBAP, the aminated hapten with structura l feature 
of DBP (27.4%).Fig. 4. DBP accumulatiAs MBP is the major metabolite of DBP, to determine whether 
MBP affects DBP binding to the MAb, The increasing concentr ation 
of MBP from 19.5 lg/mL to 10 mg/mL was added to 12.5 lg/L of 
DBP (the concentratio n of DBP giving 50% inhibition at twice as 
the titer of the MAb) at the system of icELISA. It was found that 
there is no substantial affection on inhibition ratio of DBP (Fig. 1).
3.3. Immunoﬂuorescence assays DBP exposure by dermal route 
Ten rats were epicutaneou sly smeared with DBP at 200, 
400 mg/kg bw-d or corn oil for 3 days. No dead rats were found 
in any of the groups. Immunoﬂuorescent showed that the mono- 
clonal antibody of DBP reacted with frozen tissue sections of the 
rats treated with DBP, but not with the rats treated with corn oil 
counterparts . Confocal laser scanning ﬂuorescence microscop y
indicates that DBP were immerse d in the cell actin cytoskeleton 
of cutaneous cells and/or dispersed in the cytoplasm and the peri- 
nuclear region (Fig. 2).
DBP accumulate d in subcutaneous tissue such as sweat gland, 
hair follicle, this also was shown by ﬂuorescence microscop y
(Figs. 3 and 4).
3.4. Immunoﬂuorescence assays DBP exposure by oral route 
Administered DBP at dose of 400 mg/kg bw-d for 5 days by ga- 
vage, Wistar rats were euthaniz ed. Some organs were collected and ons in hair follicle. 
Fig. 5. Immunoﬂuorescence labeling DBP on kidney. (a) Group of exposure to DBP and (b) negative control group. Wistar rats (n = 5/group) were administered either dibutyl- 
phthalate (DBP – Sigma–Aldrich) at dose of 200, 400 mg/kg bw-d, by gavage (oral route), or corn oil (vehicle). All animals were euthanized and samples were collected at 24, 
48, 72 h following 5 days exposure to DBP. Each section was ﬁxed and processed for double-immunoﬂuorescence labeling. The DBP immersed in the cell was detected with 
the monoclonal antibody of DBP. PI-stained nuclei are shown in red. In merged images, DBP are shown green and nuclei are shown in red. (For interpretation of the references 
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Immunoﬂuorescence labeling DBP on liver. (a) Group of exposure to DBP and (b) negative control group. Wistar rats (n = 5/group) were administered either dibutyl- 
phthalate (DBP – Sigma–Aldrich) at dose of 200, 400 mg/kg bw-d, by gavage (oral route), or corn oil (vehicle). All animals were euthanized and samples were collected at 24, 
48, 72 h following 5 days exposure to DBP. Each section was ﬁxed and processed for double-immunoﬂuorescence labeling. The DBP immersed in the cell was detected with 
the monoclonal antibody of DBP. PI-stained nuclei are shown in red. In merged images, DBP are shown green and nuclei are shown in red. (For interpretation of the references 
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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labeling. The distribution and accumulations of DBP were detected 
with the monoclonal antibody of DBP in the cells of liver, kidney, 
stomach and testes from each rat (Figs. 5–8). Especially, the accu- 
mulations of DBP in the liver and kidney were more obvious than 
those of other organs from their stronger ﬂuorescence intensity. The levels of ﬂuorescence intensity in those of organs were con- 
verted to integrated option density (IOD SUM) using softer Image-
Pro Plus (Fig. 9). The The IOD SUM value computed by this softer 
indicate the relative amount of immunorea ctant. According to 
the IOD SUM of these images, the relative contents of DBP in those 
of organs were compared. 
Fig. 7. Immunoﬂuorescence labeling DBP on stomach. (a) Group of exposure to DBP and (b) negative control group. Wistar rats (n = 5/group) were administered either 
dibutyl-phthalate (DBP – Sigma–Aldrich) at dose of 200, 400 mg/kg bw-d, by gavage (oral route), or corn oil (vehicle). All animals were euthanized and samples were collected 
at 24, 48, 72 h following 5 days exposure to DBP. Each section was ﬁxed and processed for double-immunoﬂuorescence labeling. The DBP immersed in the cell was detected 
with the monoclonal antibody of DBP. PI-stained nuclei are shown in red.In merged images, DBP are shown green and nuclei are shown in red. (For interpretation of the 
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 8. Immunoﬂuorescence labeling DBP on testes. (a) Group of exposure to DBP and (b) negative control group. Wistar rats (n = 5/group) were administered either dibutyl- 
phthalate (DBP – Sigma–Aldrich) at dose of 200, 400 mg/kg bw-d, by gavage (oral route), or corn oil (vehicle). All animals were euthanized and samples were collected at 24, 
48, 72 h following 5 days exposure to DBP. Each section was ﬁxed and processed for double-immunoﬂuorescence labeling. The DBP immersed in the cell was detected with 
the monoclonal antibody of DBP. PI-stained nuclei are shown in red. In merged images, DBP are shown green and nuclei are shown in red. (For interpretation of the references 
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Starting 24, 48, 72 h after the 5 days exposure to DBP, the rats 
were euthaniz ed. To study phthalate metabolize, the accumula- 
tions of DBP were evaluated by immunoﬂuorescence assays and 
measureme nt of ﬂuorescence intensity using softer Image-Pr o Plus .According to the IOD SUM value, the ﬂuorescence intensity of sam- 
ples collected at 48 or 72 h following the 5 days exposure to DBP 
was signiﬁcantly decreased in the rats given DBP at dose of 
400 mg/kg bw-d (Fig. 10 ). This signiﬁcant difference also was ob- 
served in the sections of liver (Fig. 11 ). This change indicates that 
DBP was metaboli zed to MBP or other metaboli te in 2 or 3 days. 
Fig. 9. comparing the levels of ﬂuorescence intensity in the sections of liver, kidney, 
stomach and testes using softer Image-Pro Plus .
Fig. 10. Comparing the levels of ﬂuorescence intensity of kidney in different time 
using softer Image-Pro Plus .
Fig. 11. Comparing the levels of ﬂuorescence intensity of liver in different time 
using softer Image-Pro Plus .
Fig. 12. Representative icELISA standard curves for DBP. Each point represents the 
mean of ± SD of three replicates (one plate on three different days). The standard 
curve was calculated according to the 3-parameter equation y = (AAi)/
(AA0)  100, where A is the absorbance value with no analyte present, Ai is the 
absorbance value with analyte present, A0 is the absorbance value of blank. 
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The optimal coating concentratio n of DBAP-OVA and dilution of 
MAb determined by Indirect noncompetiti ve ELISA (inELISA) were 
0.5 lg/mL and 1:1600 (1 lg/mL), respectively . An icELISA was used 
to determine DBP contents of analytes. Standard curves were ob- 
tained by plotting inhibition ratio against the standards (DBP) con- 
centration (Fig. 12 ).
After 5 days exposure to DBP through dermal route or oral 
route, samples of blood, urine, liver and kidney from the exposed 
rats were collected at 24, 48, 72 h and DBP contents of them were 
determined by Indirect noncompetitive ELISA, respectively 
(Fig. 13 ). According to the inhibition ratio and regressio n equation 
of standard curve, concentr ations of DBP in the tested tissues at 24, 
48, 72 h were calculated. The DBP contents of samples collected at 
48 h were signiﬁcantly decreased than those collected at 24 h, and 
those collected at 72 h were less than those collected at 72 h. These 
data conﬁrm the results of immunoﬂuorescence assays and indi- 
cate that DBP was metabolized in 2 or 3 days. Exposure to the same 
dose of DBP, the accumulati ons of DBP in rats exposed through der- 
mal route was less than that of oral route. To calculate the percent- 
ages of daily-admin istered dose, DBP concentrations in tested 
tissues at different time were converted from lg/L to mg/kg 
accordin g to their densities then divided by the 400 mg/kg bw-d 
of administere d dose (Table 3). Only about 0.1–0.25% of the daily 
administ ered dose by oral route or dermal route was found in 
blood, kidney, liver and urine within 24 h, about 0.03–0.1% and 
0.004–0.02% of the dose was found at 48 h and 72 h. 4. Discussions 
Phthalate s are a group of chemical s with widespread use in the 
industria l production of numerous consumer products. They are 
suspecte d to be involved in male reproductive health problems 
and have also been associated with several other health problems 
including obesity and asthma. To estimate the daily intake of 
phthalates , the main concern has been the levels of phthalate 
metaboli tes in the blood and urinary excretion (Becker et al., 
2009), whereas no data is available concerning the levels of DBP 
in other biological materials, and the environmental data consist 
primarily of estimate s. 
Fig. 13. DBP contents (a) DBP contents in blood (b) DBP contents in liver (c) DBP contents in kidney and (d) DBP contents in urine. 
Table 3
DBP concentrations in tissues at differ ent time as percentages of the daily-adminis tered dose. 
Time and route Percentage in blood (%) Percentage in liver (%) Percentage in kidney (%) Percentage in urine (%)
1 Days Oral route 0.248 ± 0.042 0.113 ± 0.019 0.158 ± 0.007 0.180 ± 0.037 
Dermal route 0.149 ± 0.014 0.084 ± 0.006 0.111 ± 0.006 0.134 ± 0.015 
2 Days Oral route 0.099 ± 0.024 0.042 ± 0.013 0.055 ± 0.017 0.106 ± 0.025 
Dermal route 0.050 ± 0.004 0.034 ± 0.006 0.036 ± 0.008 0.093 ± 0.009 
3 Days Oral route 0.013 ± 0.007 0.008 ± 0.004 0.008 ± 0.004 0.021 ± 0.013 
Dermal route 0.004 ± 0.001 0.006 ± 0.002 0.008 ± 0.004 0.018 ± 0.007 
Data are expressed as mean ± S.D (n = 5).
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testes were detected with the monoclonal antibody by immunoﬂu-
orescence assays and indirect competitive ELISA. This data give di- 
rectly evidence that indicates the distribut ion and accumulation of 
DBP in vivo. 
The concentration of DBP and MBP, are often either at or below 
detection limits. It is expensive and difﬁcult to determine the con- 
centration of DBP in organism. Both of 14C isotopic tracer method 
and chromatographi c techniques to determine the concentratio n
of DBP in previous studies are time consuming and have high 
instrumenta tion costs or high requirements for equipment. 
Although, the chromatograp hic techniques provide a low level of 
detection for phthalates, these methods require extensive puriﬁca-
tion, experienced technicians and expensive equipme nt and re- 
agents. In contrast, immunoa ssay is a fast, simple, and economic analytica l method. Because of its strong selectivity and sensitivity, 
efforts for sample cleanup can be reduced to a minimum, which 
makes the immunoassays highly convenient tools for high 
throughput studies for a large number of samples in a short period 
of time (Plaza et al., 2000 ). Neverthel ess only a few attempts have 
been made to develop sensitive and speciﬁc immunoassay s for 
phthalates . Zhang et al. has reported a competit ive ﬂuorescence
immunoa ssay for determination of DBP in water and food packag- 
ing samples based on polyclonal antibody (Zhang et al., 2006 ).
Yanaihar a et al. developed a direct competitive enzyme-link ed 
immunosorben t assay (ELISA) for phthalates also based on poly- 
clonal antibody (Yanaihara et al., 2002 ). Nevertheless, polyclonal 
antibody is restricted by immunized animals and cannot be pro- 
duced unlimitedly. Furthermore, the character of polyclonal anti- 
body from different immunized animals is different, which made 
26 Q. Zeng et al. / Food and Chemical Toxicology 56 (2013) 18–27it difﬁcult to standardize the measureme nt. Thus, more attempts 
are needed to obtain immunochem ical methodologi es capable of 
detecting this phthalate. 
In this work, we set up two novel approaches, immunoﬂuores- 
cence assays and indirect competit ive ELISA to determination of 
the distribut ion and accumulation of DBP in vivo. Double-label 
immunoﬂuorescence assays, the approach pursued in this study, 
provide with a visual approach to determination of the distribution 
and accumulation of dibutyl phthalate (DBP) in rats. It showed that 
DBP accumulations in subcutaneous tissue such as sweat gland, 
hair follicle. Confocal laser scanning ﬂuorescence microscopy indi- 
cates that DBP were immerse d in the cell actin cytoskeleton of 
cutaneous cells and/or dispersed in the cytoplasm and the perinu- 
clear region. Both of immunoﬂuorescence assays and ELISA can be 
used to detect the content of DBP in biological materials. The re- 
sults of them conﬁrmed each other. Our assays show that DBP 
accumulations in viscera being rich in fat, such as liver, kidney. Per- 
haps due to the high solubility in adipose tissue, the content of DBP 
in these organs is higher than others. Although there are several 
physiologica l barriers that DBP penetrates testes have to overcome, 
the ﬂuorescence signal indicating accumulations of DBP in testes 
can be observed by immunoﬂuorescence assays. This suggested 
that DBP can act directly on the testes. 
Dibutyl phthalate is rapidly absorbed and excreted after oral 
administrat ion as was demonstrat ed in studies in laboratory ani- 
mals (European Commiss ion, 2004 ). The data of our assays also 
conﬁrmed this. Only 0.1–0.25% of the dose was found in blood, kid- 
ney, liver and urine within 24 h. At 72 h after administ ration only 
trace amounts (<0.02%) were detected in tissues. Because the ma- 
jor part of DBP is hydrolysed to MBP and unchanged DBP was small 
amounts and hard to detect, the concentratio ns of MBP but not 
DBP itself were used to estimate absorption and excretion. How- 
ever, the absorption, distribution and accumulation of DBP in rats 
were revealed by the directly data of DBP level in this work. Com- 
paring with DBP concentrations of samples collected at different 
time following exposure to DBP, it was found that the DBP level 
of samples at 48 h after administration was 40–60% of that at 
24 h, while the DBP level at 72 h was only 10% of that at 24 h. 
The results of ELISA show that the accumulations of DBP in rats 
exposed through dermal route were less than that of oral route, 
though exposures to the same dose of DBP. This means that hu- 
mans are exposed to phthalates through ingestion is more princi- 
pal way, comparing with dermal contact. 5. Conclusions 
In this study, we have develope d a fast, simple, and economical 
analytical method to detect DBP in vivo. The distribut ion and accu- 
mulation of DBP in rats were determined by two novel approaches 
with a monoclonal antibody speciﬁc to DBP in vivo. Double-label 
immunoﬂuorescence assay provides with a visual approach to de- 
tect the distribution and content of dibutyl phthalate in biological 
materials. Both of immunoﬂuorescence assay and ELISA can be 
used to detect the content of DBP in biological materials. The re- 
sults showed that DBP accumulate d in subcutaneous tissue (sweat
gland, hair follicle) and viscera being rich in fat (liver, kidney) and 
DBP could overcome several physiologica l barriers to penetrate 
testes. The results suggested that the accumulations of DBP in rats 
exposed through dermal route were less than that of oral route and 
indicated that most of DBP was metabolized in 2 or 3 days. 6. Conﬂict of Interest 
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